BIO 112
Alternative Names: BIO112Latest Information Update: 21 May 2007
At a glance
- Originator Onc Bio
- Class
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 May 2007 Discontinued - Phase-II for Cancer in USA (unspecified route)
- 06 Oct 2005 Phase-II clinical trials in Cancer in USA (unspecified route)